Avalia Immunotherapies collapses, owes $1m to Callaghan Innovation

Avalia Immunotherapies collapses, owes $1m to Callaghan Innovation
Dr Shivali Gulab, CEO of Avalia Immunotherapies. (Image: Avalia)
Riley Kennedy
Liquidators have been appointed to a biotech outfit that helped produce a covid-19 vaccine after it failed to raise cash to help further its other project.Founded in 2015, Avalia Immunotherapies was a preclinical-stage biotech company attempting to develop a fully synthetic vaccine and immunotherapy platform. Its lead programme was targeting a functional cure for chronic Hepatitis B.After it couldn’t raise further funding for clinical development, Baker Tilly Staples Rodway’s Tony Maginness and Jared Booth were appointed liquid...

More Finance

IRD issues warning to crypto holders ahead of audits
Finance

IRD issues warning to crypto holders ahead of audits

The IRD has identified 227,000 crypto-asset users in NZ and contacted those at risk.

Staff reporters 04 Jul 2024
$1.65b project to simplify switching banks a 'flop'
Finance

$1.65b project to simplify switching banks a 'flop'

Open banking has hindered competition rather than helping it, says lobby.

AAP 04 Jul 2024
MTF to investigate bullying claims
Finance Exclusive

MTF to investigate bullying claims

Chief executive Chris Lamers said he takes the claims 'very seriously'.

Murray Jones 04 Jul 2024
Payments NZ could play key role in open banking standards
Finance

Payments NZ could play key role in open banking standards

A draft decision proposes an 18-month approval, rather than the five years requested.

Ben Moore 01 Jul 2024